Cargando…
Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx tes...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425834/ https://www.ncbi.nlm.nih.gov/pubmed/22927848 http://dx.doi.org/10.1155/2012/941495 |
_version_ | 1782241424545153024 |
---|---|
author | Malo, Teri L. Lipkus, Isaac Wilson, Tobi Han, Hyo S. Acs, Geza Vadaparampil, Susan T. |
author_facet | Malo, Teri L. Lipkus, Isaac Wilson, Tobi Han, Hyo S. Acs, Geza Vadaparampil, Susan T. |
author_sort | Malo, Teri L. |
collection | PubMed |
description | Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n = 118). Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low (RS ≤ 17), intermediate (RS = 18–30), or high (RS ≥ 31). Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval [CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake. Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients. |
format | Online Article Text |
id | pubmed-3425834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34258342012-08-27 Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting Malo, Teri L. Lipkus, Isaac Wilson, Tobi Han, Hyo S. Acs, Geza Vadaparampil, Susan T. J Cancer Epidemiol Research Article Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n = 118). Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low (RS ≤ 17), intermediate (RS = 18–30), or high (RS ≥ 31). Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval [CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake. Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients. Hindawi Publishing Corporation 2012 2012-08-13 /pmc/articles/PMC3425834/ /pubmed/22927848 http://dx.doi.org/10.1155/2012/941495 Text en Copyright © 2012 Teri L. Malo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Malo, Teri L. Lipkus, Isaac Wilson, Tobi Han, Hyo S. Acs, Geza Vadaparampil, Susan T. Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting |
title | Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting |
title_full | Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting |
title_fullStr | Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting |
title_full_unstemmed | Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting |
title_short | Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting |
title_sort | treatment choices based on oncotypedx in the breast oncology care setting |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425834/ https://www.ncbi.nlm.nih.gov/pubmed/22927848 http://dx.doi.org/10.1155/2012/941495 |
work_keys_str_mv | AT maloteril treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting AT lipkusisaac treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting AT wilsontobi treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting AT hanhyos treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting AT acsgeza treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting AT vadaparampilsusant treatmentchoicesbasedononcotypedxinthebreastoncologycaresetting |